

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTAJRK1626

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded  
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 6 NOV 10 CA/CAplus F-Term thesaurus enhanced  
NEWS 7 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available  
NEWS 8 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased to 50,000  
NEWS 9 DEC 01 CAS REGISTRY updated with new ambiguity codes  
NEWS 10 DEC 11 CAS REGISTRY chemical nomenclature enhanced  
NEWS 11 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated  
NEWS 12 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and functionality  
NEWS 13 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role  
NEWS 14 DEC 18 CA/CAplus patent kind codes updated  
NEWS 15 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased to 50,000  
NEWS 16 DEC 18 MEDLINE updated in preparation for 2007 reload  
NEWS 17 DEC 27 CA/CAplus enhanced with more pre-1907 records  
NEWS 18 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 19 JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded  
NEWS 20 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 21 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data  
NEWS 22 JAN 22 CA/CAplus updated with revised CAS roles  
NEWS 23 JAN 22 CA/CAplus enhanced with patent applications from India  
NEWS 24 JAN 29 PHAR reloaded with new search and display fields  
NEWS 25 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases  
NEWS 26 FEB 13 CASREACT coverage to be extended  
NEWS 27 Feb 15 PATDPASPC enhanced with Drug Approval numbers  
NEWS 28 Feb 15 RUSSIAPAT enhanced with pre-1994 records  
  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:13:26 ON 20 FEB 2007

=> file reg  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 17:13:36 ON 20 FEB 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6  
DICTIONARY FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10520766\Struc 2.str
```



chain nodes :

18 19 20 21 22 23 24 30

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26 27 28 29

chain bonds :

1-18 3-19 5-20 7-21 15-22 22-23 22-24 24-25 27-30

ring bonds :

1-2 1-16 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14

14-15 15-16 25-26 25-29 26-27 27-28 28-29

exact/norm bonds :

1-2 1-16 1-18 2-3 3-4 3-19 4-5 5-6 5-20 6-7 7-8 7-21 8-9 9-10 10-11

11-12 12-13 13-14 14-15 15-16 25-26 25-29 26-27 27-28 28-29

exact bonds :

15-22 22-23 22-24 24-25 27-30

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 20:CLASS  
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom  
30:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

10520766a.trn

```
=> 11
SAMPLE SEARCH INITIATED 17:13:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 66 TO ITERATE


100.0% PROCESSED 66 ITERATIONS 42 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 833 TO 1807
PROJECTED ANSWERS: 452 TO 1228
```

L2 42 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10520766\Struc 3.str



```
chain nodes :
18 19 20 21 22 23 24 30 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 25 26 27 28 29
chain bonds :
1-18 3-19 5-20 7-21 15-22 15-31 22-23 22-24 24-25 27-30
ring bonds :
1-2 1-16 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14
14-15 15-16 25-26 25-29 26-27 27-28 28-29
exact/norm bonds :
1-2 1-16 1-18 2-3 3-4 3-19 4-5 5-6 5-20 6-7 7-8 7-21 8-9 9-10 10-11
11-12 12-13 13-14 14-15 15-16 15-31 25-26 25-29 26-27 27-28 28-29
exact bonds :
15-22 22-23 22-24 24-25 27-30
```

G1:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
30:CLASS 31:CLASS
10520766a.trn

L3 STRUCTURE UPLOADED

=> d  
L3 HAS NO ANSWERS  
L3 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> l3  
SAMPLE SEARCH INITIATED 17:14:38 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 66 TO ITERATE

100.0% PROCESSED 66 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 833 TO 1807  
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> l3 full  
FULL SEARCH INITIATED 17:14:41 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1276 TO ITERATE

100.0% PROCESSED 1276 ITERATIONS 6 ANSWERS  
SEARCH TIME: 00.00.01

L5 6 SEA SSS FUL L3

=> file medline caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
172.55 172.76

FILE 'MEDLINE' ENTERED AT 17:14:48 ON 20 FEB 2007

FILE 'CAPLUS' ENTERED AT 17:14:48 ON 20 FEB 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> l5  
L6 5 L5

=> d ibib abs hitstr 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:60497 CAPLUS

DOCUMENT NUMBER: 140:111193

TITLE: Novel macrocycles for the treatment of cancer

diseases

INVENTOR(S): Hoeffle, Gerhard

PATENT ASSIGNEE(S): Gesellschaft Fuer Biotechnologische Forschung GmbH (GBF), Germany

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007483	A1	20040122	WO 2003-EP7663	20030715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS: MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
DE 10232094	A1	20040205	DE 2002-10232094	20020715
CA 2491422	A1	20040122	CA 2003-2491422	20030715
AU 2003250957	A1	20040202	AU 2003-250957	20030715
EP 1521750	A1	20050413	EP 2003-763869	20030715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005535669	T	20051124	JP 2004-520646	20030715
US 2006122241	A1	20060608	US 2005-520766	20050722
PRIORITY APPLN. INFO.:			DE 2002-10232094	A 20020715
		WO 2003-EP7663	W 20030715	

OTHER SOURCE(S): MARPAT 140:111193

GI

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB The invention relates to novel macrocycles I [R1 = Cl-6-alkyl, C2-6-alkynyl, C2-6-alkenyl; R2 = H, Cl-6-alkyl; XY = CH:CH, oxirane; R3 = halogen, Cl-6-alkyl, C2-6-alkenyl, Cl-6-heteroalkyl, CF3; R4 = bicycloaryl, bicycloheteroaryl, CR5:CHR6; R5 = H, Me; R6 = substituted aryl, heteroaryl], or a pharmaceutically acceptable, salt, solvate or hydrate thereof, and to the use thereof in the treatment of cancer diseases.

IT 647835-14-1 647835-16-3


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

RN 647835-14-1 CAPLUS

CN Oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-16-(trifluoromethyl)- (4S,7R,8S,9S,13S,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 647835-16-3 CAPLUS

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 4,17-Dioxabicyclo[4.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-

8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-3-(trifluoromethyl)-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:60492 CAPLUS

DOCUMENT NUMBER: 140:111192

TITLE: Preparation of epothilone derivatives for therapeutic use in the treatment of cancer and other cell proliferation diseases

INVENTOR(S): Hoeffle, Gerhard

PATENT ASSIGNEE(S): Gesellschaft Fuer Biotechnologische Forschung mbH (GBF), Germany

SOURCE: PCT Int. Appl., 12 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007476	A1	20040122	WO 2003-EP6066	20030610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS: MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
DE 10232094	A1	20040205	DE 2002-10232094	20020715
CA 24934609	A1	20040202	CA 2003-246409	20030610
AU 2003246409	A1	20040202	AU 2003-246409	20030610
PRIORITY APPLN. INFO.:			DE 2002-10232094	A 20020715
		WO 2003-EP6066	W 20030610	

GI



I


AB This invention relates to the preparation of epothilone derivs., such I [X = CO, SO; X = CO, if R3 = H; Y = C:CH, 2,3-oxirandiyil(epoxide) ring; R1 = alkyl, alkenyl; R2 = H, alkyl; R3 = H, alkyl, alkenyl; R4 = bicycloaryl, bicycloheteroaryl, -C(R5)=CH-R6; R5 = H, Me; R6 = aryl, heteroaryl], and their use as antitumor and cytotoxic therapeutic agents. Detailed synthesis and biol. testing data was not presented.

IT 219989-77-2P, 15-Methyllepothilone B

RL: PHU (Preparation, unclassified); THU (Therapeutic use); BIOL

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 (Biological study); PREP (Preparation); USES (Uses);  
 (prep. of epothilone derivs. for therapeutic use in the treatment of  
 cancer and other cell proliferation diseases)  
 RN 219989-77-2 CAPLUS  
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-  
 3,8,8,10,12,16-hexamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-  
 thiazolyl)ethenyl]- (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 ACCESSION NUMBER: 2002:716079 CAPLUS  
 DOCUMENT NUMBER: 137:242152  
 TITLE: Combination of epothilone analogs and  
 chemotherapeutic agents for the treatment of proliferative diseases  
 INVENTOR(S): Lee, Francis Y. F.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 125 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072085	A1	20020919	WO 2002-US6746	20020305
W: AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NO, N2, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440555	A1	20020919	CA 2002-2440555	20020305
US 2003073677	A1	20030417	US 2002-91061	20020305
EE 200300440	A	20031215	EE 2003-440	20020305
EP 1383490	A1	20040128	EP 2002-717548	20020305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007961	A	20040420	BR 2002-7961	20020305
CN 1496256	A	20040512	CN 2002-806571	20020305
HU 200400203	A2	20040830	HU 2004-203	20020305
JP 2004529904	T	20040930	JP 2002-571044	20020305
BG 108137	A	20050131	BG 2003-108137	20030828
ZA 2003007123	A	20041213	ZA 2003-7123	20030911
NO 2003004056	A	20031105	NO 2003-4056	20030912
US 2004214871	A1	20041028	US 2004-850072	20040520
US 2005159461	A1	20050721	US 2004-9579	20041210
PRIORITY APPLN. INFO.:				
			US 2001-316395P	P 20010831
			US 2002-91061	A3 20020305
			WO 2002-US6746	W 20020305

OTHER SOURCE(S): MARPAT 137:242152  
 AB The invention discloses use of a combination of epothilone analogs and  
 antitumor agents for the treatment and prevention of proliferative  
 disorders.  
 IT 219989-77-2 219989-79-4 219989-80-7  
 219989-81-8

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses);  
 (combination of epothilone analogs and antitumor agents for treatment  
 of proliferative diseases)  
 RN 219989-77-2 CAPLUS  
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-  
 3,8,8,10,12,16-hexamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-  
 thiazolyl)ethenyl]- (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 219989-79-4 CAPLUS  
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione,  
 7,11-dihydroxy-3,8,8,10,12-  
 pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-  
 (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 219989-80-7 CAPLUS  
 CN 4-Oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-  
 16-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 219989-81-8 CAPLUS  
 CN 4-Oxacyclohexadec-13-ene-2,6-dione,  
 4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-16-  
 [(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]- (4S,7R,8S,9S,13S,16S)-  
 (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 Absolute stereochemistry.  
 Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 (Continued)  
 ACCESSION NUMBER: 2002:657954 CAPLUS  
 DOCUMENT NUMBER: 137:195554  
 TITLE: Treatment of refractory tumors using epothilone derivatives  
 INVENTOR(S): Lee, Francis Y. F.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 38 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066038	A1	20020829	WO 2002-US4255	20020206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2438610	A1	20020829	CA 2002-2438610	20020206
EE 200300396	A	20031215	EE 2003-396	20020206
HU 200303175	A2	20031229	HU 2003-3175	20020206
EP 1385529	A1	20040204	EP 2002-714885	20020206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004522774	T	20040729	JP 2002-565596	20020206
BR 2002007487	A	20040810	BR 2002-7487	20020206
CN 1774253	A	20060517	CN 2002-805251	20020206
US 2002165258	A1	20021107	US 2002-72123	20020208
US 6686380	B2	20040203		
BG 108075	A	20050430	BG 2003-108075	20030807
ZA 2003006173	A	20041123	ZA 2003-6173	20030808
NO 2003003684	A	20031013	NO 2003-3684	20030819
PRIORITY APPLN. INFO.:			US 2001-269836P	P 20010220
			WO 2002-US4255	W 20020206

OTHER SOURCE(S): MARPAT 137:195554  
 AB Methods of treating tumors in a mammal, especially a human that has demonstrated resistance to other chemotherapeutic agents, is disclosed. Specifically, methods of the present invention are effective in tumors that have initially been unresponsive to taxane therapy, or have developed resistance during the course of treatment. The methods of the present invention comprise administering epothilone derivs. selected from those represented by the formula. The subject epothilone derivs. are advantageous in addition to their enhanced potency and effectiveness against tumors that have demonstrated resistance to therapy with taxane oncol.

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 agents in that they are efficacious upon oral administration.  
 IT 219989-77-2 219989-79-4 219989-80-7  
 219989-81-8  
 RL: PAC (Pharmacological activity); THU (Therapeutic use): BIOL (Biological study); USES (Uses): (treatment of refractory tumors using epothilone derivs. in relation to mechanism and drug resistance)  
 RN 219989-77-2 CAPLUS  
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-3,8,8,10,12,16-hexamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 219989-79-4 CAPLUS  
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-3,8,8,10,12- pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 219989-80-7 CAPLUS  
 CN Oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-16-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (4S,7R,8S,9S,13S,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 219989-81-8 CAPLUS  
 CN Oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,16-pentamethyl-16-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (4S,7R,8S,9S,13S,16S)- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 Absolute stereochemistry.  
 Double bond geometry as shown.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 ACCESSION NUMBER: 1999:64791 CAPLUS  
 DOCUMENT NUMBER: 130:139205  
 TITLE: syntheses of epothilone derivatives and intermediates for use in treatment of hyperproliferative cellular disease  
 INVENTOR(S): Vite, Gregory D.; Borrelli, Robert M.; Kim, Soong-hoon; Johnson, James A.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 70 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902514	A2	19990121	WO 1998-US12550	19980616
WO 9902514	A3	20010510		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6605599	B1	20030812	US 1998-84542	19980526
CA 2296012	A1	19990121	CA 1998-2296012	19980616
AU 9879720	A	19990208	AU 1998-79720	19980616
AU 731497	B2	20010329		
EP 1019389	A2	20000719	EP 1998-930300	19980616
EP 1019389	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9810555	A	20000815	BR 1998-10555	19980616
EE 200000013	A	20000815	EE 2000-13	19980616
EE 4566	B1	20051215		
TR 200000065	T2	20001121	TR 2000-20000065	19980616
NZ 501198	A	20010928	NZ 1998-501198	19980616
JP 2002512634	T	20020423	JP 1999-508673	19980616
HU 200103111	A2	20020429	HU 2001-3111	19980616
RU 2213741	C2	20031010	RU 2000-102893	19980616
EP 1493738	A1	20050105	EP 2004-21059	19980616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1526133	A1	20050427	EP 2004-28580	19980616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1531153	A1	20050518	EP 2004-28581	19980616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 309236	T	20051115	AT 1998-930300	19980616
IL 133613	A	20051120	IL 1998-133613	19980616
RO 120340	B1	20051230	RO 1999-1332	19980616

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 ES 2251088 T3 20060416 ES 1998-930300 19980616  
 TW 562802 B 20031121 TW 1998-87110722 19980702  
 ZA 9805938 A 20000110 ZA 1998-5938 19980706  
 MX 9911452 A 20000630 MX 1999-11452 19991209  
 LT 4743 B 20001227 LT 1999-153 19991223  
 NO 2000000076 A 20000107 NO 2000-76 20000107  
 NO 322494 B1 20061016  
 BG 64952 B1 20061031 BG 2000-104068 20000110  
 LV 12565 B 20010420 LV 2000-17 20000202  
 HK 1026905 A1 20060331 HK 2000-106086 20000926  
 US 2003220295 A1 20031127 US 2003-405886 20030403  
 US 7125699 B2 20061024  
 US 2006287371 A1 20061221 US 2006-512623 20060830  
 PRIORITY APPLN. INFO.: US 1997-51951P P 19970708  
 US 1997-67524P P 19971204  
 US 1998-64542 A1 19980526  
 EP 1998-930300 A3 19980616  
 WO 1998-US12550 W 19980616  
 US 2003-405886 A1 20030403

OTHER SOURCE(S): MARPAT 130:139205  
 GI .




AB Syntheses of epothilone derivs. (I) (R = H, Me; A = CH<sub>2</sub>, O, NH; X = H when bond double,  $\alpha$ -epoxy when bond single) and intermediates for use in treatment of hyperproliferative cellular disease are described.

IT 219989-77-2 219989-79-4 219989-80-7  
 ZI 19989-81-8  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)  
 (syntheses of epothilone analogs and intermediates for use in treatment of hyperproliferative cellular disease)  
 RN 219989-77-2 CAPLUS  
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]- (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 thiazolyl)ethenyl]-, (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.  
 Double bond geometry as shown.



RN 219989-79-4 CAPLUS  
 CN 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]- (1S,3S,7S,10R,11S,12S,16R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 219989-80-7 CAPLUS  
 CN Oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-16-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]- (4S,7R,8S,9S,13Z,16S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 219989-81-8 CAPLUS  
 CN Oxacyclohexadec-13-ene-2,6-dione, 4,8-dihydroxy-5,5,7,9,16-pentamethyl-16-

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 [(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-, (4S,7R,8S,9S,13Z,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



Page 11

=> log y  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

	SINCE FILE	TOTAL
	ENTRY	SESSION
	27.33	200.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE	TOTAL
	ENTRY	SESSION
	-3.90	-3.90

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:15:42 ON 20 FEB 2007